No Data
No Data
Citigroup: rates Sino Biopharm as "buy" with a target price of HKD 6.8.
According to a research report released by Citigroup, due to the strong sales growth of biosimilars and innovative drugs, it is expected that Sino Biopharmaceutical (01177) will perform well in the first half of the year, with a year-on-year profit growth of approximately 10%. Due to the increased sales of biosimilars, G-CSF, and Cataplasms, the company is expected to have higher visibility in the second half of the year. The bank has initiated a 30-day upside catalyst observation on the company, with a target price of HKD 6.8 and a rating of "buy".
Citi: Rated buy for Sino Biopharmaceutical (01177) with a target price of HKD 6.8.
Citigroup has initiated a 30-day upward catalyst observation on Sino Biopharmaceuticals (01177) in China.
Sino Biopharmaceutical Gets Selected by S&P Global, FTSE4Good Index for ESG Practices
Sino Biopharm (01177.HK): ESG performance recognized by S&P Global and FTSE Russell.
Sino Biopharm (01177.HK) announced on July 19th that the group has been recognized by multiple global sustainable development authorities, such as S&P Global and FTSE Russell, based on its continuous and stable environmental, social and corporate governance (ESG) performance.
Sino Biopharmaceutical's Phase-3 Trial of Breast Cancer Drug Reaches Primary Endpoint
Sino Biopharm (01177) under the Hong Kong stock connect program: Phase III clinical trials related to breast cancer treatment achieve the predetermined primary endpoint.
Sinobiopharm (01177) announced that the phase III clinical trial (NCT05375461) of type 1 innovative drug Culmerciclib (TQB3616) developed by the group and combined with fluvisinque injection for the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer that has been treated with endocrine therapy in the past has completed mid-term analysis and has achieved the preset primary endpoint after being reviewed by the Independent Data Monitoring Committee (IDMC). The research results will be published in academic journals or major academic conferences.
No Data